试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-03
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
编号:NCT03539484登记状态:提前终止企业 / 申办者:Hoffmann-La Roche
药物 / 成分:RO7172508、Obinutuzumab、Tocilizumab
登记的停止原因(原文):Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-03
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
编号:NCT03597282登记状态:提前终止企业 / 申办者:BioNTech US Inc.
药物 / 成分:NEO-PV-01、Nivolumab、Adjuvant、APX005M
登记的停止原因(原文):Closed due to historically slow enrollment compounded by the COVID-19 pandemic.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-03
A Clinical Study to Evaluate the Safety, Tolerability, PK, PD, and Efficacy of KBP-089 in Patients With T2DM
编号:NCT03907202登记状态:提前终止企业 / 申办者:KeyBioscience AG
药物 / 成分:Daily injection of KBP/placebo for up to 28 days
登记的停止原因(原文):The trial was planned to be conducted in 4 cohorts but was terminated after completion of Cohort 2 for strategic reasons due to limited PD effects.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)
编号:NCT00182455登记状态:提前终止企业 / 申办者:McMaster University
药物 / 成分:Topiramate、Placebo
登记的停止原因(原文):loss of funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Doxycycline, Temozolomide and Ipilimumab in Melanoma
编号:NCT01590082登记状态:提前终止企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:Doxycycline、Ipilimumab、Temozolomide
登记的停止原因(原文):Accrual slow due to alternate trials and treatment options.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure
编号:NCT02857309登记状态:提前终止企业 / 申办者:Impulse Dynamics
药物 / 成分:OPTIMIZER、Optimal medical therapy
登记的停止原因(原文):Slow enrolment.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Trabectedin Maintenance Post 1st-line in STS
编号:NCT02929394登记状态:提前终止企业 / 申办者:European Organisation for Research and Treatment of Cancer - EORTC
药物 / 成分:Trabectedin
登记的停止原因(原文):Poor accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy
编号:NCT03225924登记状态:提前终止企业 / 申办者:The Lymphoma Academic Research Organisation
药物 / 成分:Entospletinib、Rituximab、Cyclophosphamide、Doxorubicin
登记的停止原因(原文):Stop of drug development
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
编号:NCT03241810登记状态:提前终止企业 / 申办者:Elevation Oncology
药物 / 成分:Seribantumab、Fulvestrant、Placebo
登记的停止原因(原文):Merrimack Inc. terminated the trial early due to business decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2020-09-02
Preventing Recurrent Urinary Tract Infections With α-D-mannose
编号:NCT03497598登记状态:提前终止企业 / 申办者:Kantonsspital Aarau
药物 / 成分:Mannose、Lactose
登记的停止原因(原文):not enough patients
查看官方原始记录 ↗